Chronic intranasal oxytocin alleviates cognitive impairment and reverses oxytocin signaling upregulation in MK801-induced mice
- Psychoneuroendocrinology. 2024 Oct:168:107138. doi: 10.1016/j.psyneuen.2024.107138.
- 1. Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.
- 2. Department of Biochemistry and Molecular Biology, Hunan University of Chinese Medicine, Changsha, China.
- 3. Department of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, China.
- 4. Department of Laboratory Medicine, The Second Xiangya Hospital, Central South University, Changsha, China. Electronic address: [email protected].
Objective: Cognitive impairment, especially impaired social cognition, is largely responsible for the deterioration of the social life of patients with schizophrenia (SZ). Oxytocin (OT) is a neuropeptide that offers promising therapy for SZ. This study aimed to explore whether OT could affect dizocilpine (MK801)-induced cognitive impairment and to investigate the effect of exogenous OT on the endogenous OT system in the hippocampus.
Methods: The SZ mouse model was established by repeated administration of dizocilpine [MK801, 0.6 mg/kg, intraperitoneal (i.p.)], and then OT (6-60 μg/kg, intranasal) or risperidone (0.3 mg/kg, i.p.) was administered to explore the effect of OT on cognitive impairment.
Results: OT at a dose of 6 μg/kg alleviated MK801-induced hyperactivity, sociability impairment, and spatial memory impairment. OT at a dose of 20 or 60 μg/kg attenuated the hyperactivity and social novelty impairment. In MK801-injected mice, the compensatory upregulation of OT mRNA in the hippocampus was reversed by three OT doses, whereas 60 μg/kg OT reversed the compensatory upregulation of CD38 protein expression.
Conclusion: OT alleviated cognitive impairment in the SZ mouse model to varying degrees, reversing the compensatory upregulation of OT signaling in the hippocampus.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: iGluRResearch Areas: Neurological Disease
-
-
Research Areas: Neurological Disease